
FutureBridge

FUTURE OF CELL AND GENE THERAPIES (CGT)

Global Trends and Approvals In Cancer


New Hopes and Scientific Rationale


Advancing CGT to Unprecedented Success



CT: Cell Therapy; GT: Gene Therapy; SCM: Supply Chain Management; TILs: Tumor-infiltrating lymphocytes 'Approvals in Limited Countries refer to Regulatory approvals granted in single geographical area Source: FutureBridge Analysis, Scopus, Orbit, ClinicalTrials.gov

Distribution of CGT Studies in Oncology - Global





Conclusion

- The CGT landscape is rapidly expanding, fueled by rising approvals, clinical trials, patents, publications, and global corporate and academic participation.
- New markets like India are catching up, US and China remain the major markets in terms of innovation and need
- Collaboration and open innovation are the major success drivers

About FutureBridge

FutureBridge is a techno-commercial consulting and advisory company. We track and advise on the future of industries from a 1-to-25-year perspective to keep you ahead of the technology curve, propel your growth, Identify new opportunities, markets and business models, answer your unknowns, and facilitate best-fit solutions and partnerships using our platforms, programs, and access to global ecosystems and players.